ADC Therapeutics SA - Asset Resilience Ratio
ADC Therapeutics SA (ADCT) has an Asset Resilience Ratio of 61.82% as of March 2020. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ADC Therapeutics SA short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (None–None)
This chart shows how ADC Therapeutics SA's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is ADC Therapeutics SA's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down ADC Therapeutics SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ADCT long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $231.10 Million | 61.82% |
| Total Liquid Assets | $231.10 Million | 61.82% |
Asset Resilience Insights
- Very High Liquidity: ADC Therapeutics SA maintains exceptional liquid asset reserves at 61.82% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ADC Therapeutics SA Industry Peers by Asset Resilience Ratio
Compare ADC Therapeutics SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Alkem Laboratories Limited
NSE:ALKEM |
Drug Manufacturers - Specialty & Generic | 31.91% |
|
Humanwell Healthcare Group Co Ltd
SHG:600079 |
Drug Manufacturers - Specialty & Generic | 2.44% |
|
Suven Pharmaceuticals Limited
NSE:SUVENPHAR |
Drug Manufacturers - Specialty & Generic | 6.76% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 1.37% |
|
Joincare Pharmaceutical Group Industry Co Ltd
SHG:600380 |
Drug Manufacturers - Specialty & Generic | 1.86% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 9.44% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
Annual Asset Resilience Ratio for ADC Therapeutics SA (None–None)
The table below shows the annual Asset Resilience Ratio data for ADC Therapeutics SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| No yearly data available. | ||||
About ADC Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatme… Read more